CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 26 enrolled
Drug / intervention
Methotrexate +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02330380
NCT02330380N/ACompleted
CompareCT.gov

Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation

University Hospitals Cleveland Medical Center·observational·Posted Jan 1, 2015·Updated Oct 13, 2017

In Brief

An observational study evaluating Methotrexate, Ustekinumab, and 5 other interventions for Psoriasis and Inflammation. Completed, enrolled 26 participants across 1 site.

Detailed Summary

This is a prospective longitudinal observational pilot study of psoriasis patients on continuous standard-of-care systemic therapeutics to determine the level of change in established (plasma/serum) and investigative (cellular) biomarkers that are associated with increased risk of CVD events. The final endpoint of the proposed study will be a ranking of the examined biomarkers based upon an integrated assessment of biomarker behavior over time. Secondary outcomes will assess changes in coronary artery calcification scoring, PET-MRI, skin biopsies, and clinical improvement.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis, Inflammation
CountriesUnited States
CollaboratorsNational Psoriasis Foundation

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 1, 2015
Enrollment StartApr 1, 2013
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 11.5 years ago

Interventions

Methotrexatedrug

Subjects will receive Methotrexate as detailed in the "Group" description.

Ustekinumabdrug

Subjects will receive Ustekinumab as detailed in the "Group" description.

Etanerceptdrug

Subjects will receive Etanercept as detailed in the "Group" description.

Adalimumabdrug

Subjects will receive Adalimumab as detailed in the "Group" description.

Acitretindrug

Subjects will receive Acitretin as detailed in the "Group" description.

UVB Excimer Laserother

Subjects will receive UVB Excimer Laser therapy as detailed in the "Group" description.

Narrowband UVBother

Subjects will receive Narrowband UVB as detailed in the "Group" description.